Proton pump inhibitors, bone and phosphocalcic metabolism. Philippoteaux, C., Paccou, J., Chazard, E., & Cortet, B. Joint Bone Spine, 91(5):105714, March, 2024. doi abstract bibtex Proton pump inhibitors (PPIs) are widely used for acid-related gastrointestinal disorders; however, concerns have arisen about their prolonged and inappropriate use. Although generally considered safe, recent evidence has linked PPI use with an increased risk of kidney disease, stomach cancer, pneumonia, dementia, cardiovascular events and potential bone health problems. This systematic review examines the effects of PPIs on bone health, including osteoporosis and changes in phosphocalcic and magnesium metabolism, through a comprehensive analysis of the recent literature. The relationship between PPIs, bone mineral density and fracture risk, especially in populations with comorbidities, is complex and we propose a focus based on recent data. Studies of the effect of PPI use on bone mineral density have shown mixed results and require further investigation. Observational studies have indicated an increased risk of fractures, particularly vertebral fractures, associated with PPI use. Recent meta-analyses have confirmed an association between PPI use and hip fractures with a dose-dependent effect. More recently, PPIs have been associated with serious disturbances in phosphocalcic and magnesium metabolism that require careful management and discontinuation. Proton pump inhibitor-induced hypomagnesemia (PPIH) is a well-established phenomenon. In addition, hypocalcemia secondary to severe hypomagnesemia has been described. Despite growing evidence of PPI-related risks, further research is essential to better understand the complex mechanisms, as most data are from observational studies and do not establish a causal relationship. This review emphasizes the need for judicious prescription practices, particularly in long-term use scenarios and rheumatological contexts.
@article{philippoteaux_proton_2024,
title = {Proton pump inhibitors, bone and phosphocalcic metabolism},
volume = {91},
issn = {1778-7254},
doi = {10.1016/j.jbspin.2024.105714},
abstract = {Proton pump inhibitors (PPIs) are widely used for acid-related gastrointestinal disorders; however, concerns have arisen about their prolonged and inappropriate use. Although generally considered safe, recent evidence has linked PPI use with an increased risk of kidney disease, stomach cancer, pneumonia, dementia, cardiovascular events and potential bone health problems. This systematic review examines the effects of PPIs on bone health, including osteoporosis and changes in phosphocalcic and magnesium metabolism, through a comprehensive analysis of the recent literature. The relationship between PPIs, bone mineral density and fracture risk, especially in populations with comorbidities, is complex and we propose a focus based on recent data. Studies of the effect of PPI use on bone mineral density have shown mixed results and require further investigation. Observational studies have indicated an increased risk of fractures, particularly vertebral fractures, associated with PPI use. Recent meta-analyses have confirmed an association between PPI use and hip fractures with a dose-dependent effect. More recently, PPIs have been associated with serious disturbances in phosphocalcic and magnesium metabolism that require careful management and discontinuation. Proton pump inhibitor-induced hypomagnesemia (PPIH) is a well-established phenomenon. In addition, hypocalcemia secondary to severe hypomagnesemia has been described. Despite growing evidence of PPI-related risks, further research is essential to better understand the complex mechanisms, as most data are from observational studies and do not establish a causal relationship. This review emphasizes the need for judicious prescription practices, particularly in long-term use scenarios and rheumatological contexts.},
language = {eng},
number = {5},
journal = {Joint Bone Spine},
author = {Philippoteaux, Cécile and Paccou, Julien and Chazard, Emmanuel and Cortet, Bernard},
month = mar,
year = {2024},
pmid = {38458487},
keywords = {Hypocalcemia, Hypomagnesemia, Osteoporosis, Osteoporotic fractures, Proton pump inhibitors},
pages = {105714},
}
Downloads: 0
{"_id":"TfyJvDoJH2FuWDtwi","bibbaseid":"philippoteaux-paccou-chazard-cortet-protonpumpinhibitorsboneandphosphocalcicmetabolism-2024","author_short":["Philippoteaux, C.","Paccou, J.","Chazard, E.","Cortet, B."],"bibdata":{"bibtype":"article","type":"article","title":"Proton pump inhibitors, bone and phosphocalcic metabolism","volume":"91","issn":"1778-7254","doi":"10.1016/j.jbspin.2024.105714","abstract":"Proton pump inhibitors (PPIs) are widely used for acid-related gastrointestinal disorders; however, concerns have arisen about their prolonged and inappropriate use. Although generally considered safe, recent evidence has linked PPI use with an increased risk of kidney disease, stomach cancer, pneumonia, dementia, cardiovascular events and potential bone health problems. This systematic review examines the effects of PPIs on bone health, including osteoporosis and changes in phosphocalcic and magnesium metabolism, through a comprehensive analysis of the recent literature. The relationship between PPIs, bone mineral density and fracture risk, especially in populations with comorbidities, is complex and we propose a focus based on recent data. Studies of the effect of PPI use on bone mineral density have shown mixed results and require further investigation. Observational studies have indicated an increased risk of fractures, particularly vertebral fractures, associated with PPI use. Recent meta-analyses have confirmed an association between PPI use and hip fractures with a dose-dependent effect. More recently, PPIs have been associated with serious disturbances in phosphocalcic and magnesium metabolism that require careful management and discontinuation. Proton pump inhibitor-induced hypomagnesemia (PPIH) is a well-established phenomenon. In addition, hypocalcemia secondary to severe hypomagnesemia has been described. Despite growing evidence of PPI-related risks, further research is essential to better understand the complex mechanisms, as most data are from observational studies and do not establish a causal relationship. This review emphasizes the need for judicious prescription practices, particularly in long-term use scenarios and rheumatological contexts.","language":"eng","number":"5","journal":"Joint Bone Spine","author":[{"propositions":[],"lastnames":["Philippoteaux"],"firstnames":["Cécile"],"suffixes":[]},{"propositions":[],"lastnames":["Paccou"],"firstnames":["Julien"],"suffixes":[]},{"propositions":[],"lastnames":["Chazard"],"firstnames":["Emmanuel"],"suffixes":[]},{"propositions":[],"lastnames":["Cortet"],"firstnames":["Bernard"],"suffixes":[]}],"month":"March","year":"2024","pmid":"38458487","keywords":"Hypocalcemia, Hypomagnesemia, Osteoporosis, Osteoporotic fractures, Proton pump inhibitors","pages":"105714","bibtex":"@article{philippoteaux_proton_2024,\n\ttitle = {Proton pump inhibitors, bone and phosphocalcic metabolism},\n\tvolume = {91},\n\tissn = {1778-7254},\n\tdoi = {10.1016/j.jbspin.2024.105714},\n\tabstract = {Proton pump inhibitors (PPIs) are widely used for acid-related gastrointestinal disorders; however, concerns have arisen about their prolonged and inappropriate use. Although generally considered safe, recent evidence has linked PPI use with an increased risk of kidney disease, stomach cancer, pneumonia, dementia, cardiovascular events and potential bone health problems. This systematic review examines the effects of PPIs on bone health, including osteoporosis and changes in phosphocalcic and magnesium metabolism, through a comprehensive analysis of the recent literature. The relationship between PPIs, bone mineral density and fracture risk, especially in populations with comorbidities, is complex and we propose a focus based on recent data. Studies of the effect of PPI use on bone mineral density have shown mixed results and require further investigation. Observational studies have indicated an increased risk of fractures, particularly vertebral fractures, associated with PPI use. Recent meta-analyses have confirmed an association between PPI use and hip fractures with a dose-dependent effect. More recently, PPIs have been associated with serious disturbances in phosphocalcic and magnesium metabolism that require careful management and discontinuation. Proton pump inhibitor-induced hypomagnesemia (PPIH) is a well-established phenomenon. In addition, hypocalcemia secondary to severe hypomagnesemia has been described. Despite growing evidence of PPI-related risks, further research is essential to better understand the complex mechanisms, as most data are from observational studies and do not establish a causal relationship. This review emphasizes the need for judicious prescription practices, particularly in long-term use scenarios and rheumatological contexts.},\n\tlanguage = {eng},\n\tnumber = {5},\n\tjournal = {Joint Bone Spine},\n\tauthor = {Philippoteaux, Cécile and Paccou, Julien and Chazard, Emmanuel and Cortet, Bernard},\n\tmonth = mar,\n\tyear = {2024},\n\tpmid = {38458487},\n\tkeywords = {Hypocalcemia, Hypomagnesemia, Osteoporosis, Osteoporotic fractures, Proton pump inhibitors},\n\tpages = {105714},\n}\n\n","author_short":["Philippoteaux, C.","Paccou, J.","Chazard, E.","Cortet, B."],"key":"philippoteaux_proton_2024","id":"philippoteaux_proton_2024","bibbaseid":"philippoteaux-paccou-chazard-cortet-protonpumpinhibitorsboneandphosphocalcicmetabolism-2024","role":"author","urls":{},"keyword":["Hypocalcemia","Hypomagnesemia","Osteoporosis","Osteoporotic fractures","Proton pump inhibitors"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/1597782/collections/MSB7W4UM/items?key=gxIPM4PJtMVcB8OpssCWodtP&format=bibtex&limit=100&start=0&sort=date","dataSources":["doevpoZ8x7wJceFTM"],"keywords":["hypocalcemia","hypomagnesemia","osteoporosis","osteoporotic fractures","proton pump inhibitors"],"search_terms":["proton","pump","inhibitors","bone","phosphocalcic","metabolism","philippoteaux","paccou","chazard","cortet"],"title":"Proton pump inhibitors, bone and phosphocalcic metabolism","year":2024}